

HPTN at R4P 2018

Sunday, 21 October
Satellite Session - 15:00 - 18:00 - Marsella

Title	Chairs
Engagement of African MSM in HIV Prevention Research: Effective Recruitment and Retention	K. Mayer S. Adebajo

Satellite Session - 16:00 - 18:00 - Estrasburgo

Title	Chairs
State of the Art of HIV bNAbs for Prevention of HIV Infection	L. Corey M. Cohen

Monday, 22 October
Satellite Session - 8:30 - 11:30 - Bristol

Title	Chairs
Current State of Play: PrEP Implementation Update and Challenges	W. El-Sadr R. Baggaley

Satellite Session - 12:00 - 15:00 - Burdeos

Title	Chairs
It Only Hurts a Little: Long-Acting Injectables for HIV Prevention and Treatment	S. Shoptaw R. Landovitz

HPTN at R4P 2018

Tuesday, 23 October *Oral Presentation - 13:00 - 14:30 - Londres*

Abstract	Title	Presenter
OA05.01 13:00 – 13:15	Acceptability of Long-Acting Injectable Cabotegravir (CAB LA) in HIV-Uninfected Individuals: HPTN 077	B. Tolley

Poster Presentations - 17:30 - 19:30 - Poster Hall

Abstract	Title	Presenter
P03.57	Impact of Childhood Sexual Abuse Among Sub-Saharan African Men who Have Sex With Men and Transgender Women in HPTN 075	Y. Mbilizi
P05.01	Finding MSM who may be Potential Amplified HIV Transmitters: Results from HPTN 078	T. Gamble
P05.17LB	Retention in the Ongoing AMP Trials of VRC01, a Broadly Neutralizing Antibody (bnAb) to Prevent HIV in Women, MSM & Transgender (TG) People	P. Andrew
P14.43	Differences by Wave of Respondent-driven Sampling Recruitment Among Gay Men and Other Men Who Have Sex With Men in 4 U.S. Cities: Results From HPTN 078	S. Baral
P16.01	Understanding HIV Transmission Dynamics and the Impact of Past HIV Interventions Among MSM in Baltimore: A Modelling Study for HPTN 078	R. Stilhol
P25.05	Interviewer Adjustment of Smart Pillbox Monitoring Did Not Improve Accuracy in Measuring Oral PrEP Adherence in HPTN 067	B. Dye

Wednesday, 24 October *Oral Presentation - 10:30 - 12:00 - Bristol*

Abstract	Title	Presenter
OA10.04LB 11:15 – 11:30	HIV Incidence Among Men Who Have Sex With Men and Transgender Women in Sub-Saharan Africa: Findings From the Multi-Country HPTN 075 Cohort Study	T. Sandfort
OA10.06 11:45 – 12:00	An Integrated Intervention to Increase ART and MAT Reduces Mortality Among PWID: Results From the HPTN 074 Randomized Trial	K. Dumchev

Oral Presentation - 13:00 - 14:30 - Marsella

Abstract	Title	Presenter
OA15.06LB 14:15 – 14:30	Tail-phase Safety, Tolerability and Pharmacokinetics of Long-acting Injectable Cabotegravir in HIV-uninfected Individuals: HPTN 077 Final Results	R. Landovitz

HPTN at R4P 2018

Wednesday, 24 October
Poster Discussion - 16:45 - 17:30 - Oxford

Abstract	Title	Presenter
PD08.01 16:45 – 16:54	Adaptive Non-Inferiority Margins in HIV Prevention Trials	B. Hanscom

Poster Presentations - 17:30 - 19:30 - Poster Hall

Abstract	Title	Presenter
P03.46	Stigma, Self-Esteem and Depressive Symptoms in HIV-Infected Men Who Have Sex With Men and Transgender Women in Sub-Saharan Africa (HPTN 075)	E. Hamilton
P05.06	Sexual Risk and Study Drug Detection in MSM Participants in a Phase II Study of Maraviroc (MVC) +/- Tenofovir DF (TDF) or FTC versus TDF/FTC for PrEP	K. Mayer
P05.18LB	Antibody Mediated Prevention: Proof-of-Concept, Randomized, Blinded, Placebo-Controlled Trials to Assess Safety and Efficacy of VRC01 to Prevent HIV-1	S. Edupuganti
P25.10	Challenges to Collecting PrEP Adherence Data in the New York City (NYC) Site of the HPTN 067 Study	S. Mannheimer

Thursday, 25 October
Oral Presentation - 8:30 - 10:30 - Oxford

Abstract	Title	Presenter
0A18.01 8:30-8:45	Beneficial Impacts Related to Participating in an International HIV Prevention Trial Involving People Who Inject Drugs	J. Sugarman
0A18.02 8:45 – 9:00	Standardized Metrics Can Reveal Region-Specific Opportunities in Community Engagement to Aid Recruitment in HIV Prevention Trials	G. Broder